In our study, MGMT promoter methylation status successfully stratified astrocytoma patients treated with adjuvant TMZ chemotherapy into two groups with significant prognostic differences, consistent with previous research [6]. Here, MGMT is linked to astrocytoma (excluding glioblastoma).